Company intelligence / Profile preview

PsiVac Ltd

London, United Kingdompsivac.com ↗

Ownership: Private
Development stage: Phase 1

Overview

PsiVac has developed a portfolio of oncolytic adenoviruses with preclinical data showing high efficacy and safety in killing a broad range of tumor cells. Their lead candidate Ixovex‑1 is moving into Phase I/II clinical trials for solid tumors. The company has demonstrated compelling preclinical results in multiple tumor types and established manufacturing partnerships to support clinical development.

Therapeutic areas: Oncology
Modalities: Oncolytic viruses (genetically modified adenoviruses)
Industry: Biotech

Drug pipeline

1 asset

Ixovex-1

Phase 1

Indications: Head and neck squamous cell carcinoma, Bladder cancer, Liver cancer, Pancreatic cancer, Ovarian cancer

Partnerships

Lonza Group AG – strategic agreement for cGMP manufacturing of Ixovex‑1 product at Lonza’s Houston facility

Beyond the preview

Go deeper on PsiVac Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PsiVac Ltd.

Explore the full profile